Mark J. Mulligan

24.3k total citations · 3 hit papers
150 papers, 8.5k citations indexed

About

Mark J. Mulligan is a scholar working on Infectious Diseases, Epidemiology and Virology. According to data from OpenAlex, Mark J. Mulligan has authored 150 papers receiving a total of 8.5k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Infectious Diseases, 63 papers in Epidemiology and 54 papers in Virology. Recurrent topics in Mark J. Mulligan's work include HIV Research and Treatment (46 papers), SARS-CoV-2 and COVID-19 Research (26 papers) and HIV/AIDS Research and Interventions (20 papers). Mark J. Mulligan is often cited by papers focused on HIV Research and Treatment (46 papers), SARS-CoV-2 and COVID-19 Research (26 papers) and HIV/AIDS Research and Interventions (20 papers). Mark J. Mulligan collaborates with scholars based in United States, France and United Kingdom. Mark J. Mulligan's co-authors include Rafi Ahmed, Srilatha Edupuganti, Paul A. Goepfert, Gerd Ritter, Richard W. Compans, Nadine Rouphael, Steffanie Sabbaj, Bali Pulendran, Rama Akondy and Joseph D. Miller and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and JAMA.

In The Last Decade

Mark J. Mulligan

148 papers receiving 8.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans

2008 809 citations Rama Akondy, Eva K. Lee et al. profile →
Molecular signatures of antibody responses derived from a systems biology study of five human vaccines

2013 462 citations Nadine Rouphael, Sai Duraisingham et al. profile →
Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus

2016 423 citations Srilatha Edupuganti, Mark J. Mulligan et al. profile →

Peers

Countries citing papers authored by Mark J. Mulligan

Since Specialization

Citations

This map shows the geographic impact of Mark J. Mulligan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. Mulligan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. Mulligan more than expected).

Fields of papers citing papers by Mark J. Mulligan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark J. Mulligan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. Mulligan. The network helps show where Mark J. Mulligan may publish in the future.

Co-authorship network of co-authors of Mark J. Mulligan

This figure shows the co-authorship network connecting the top 25 collaborators of Mark J. Mulligan. A scholar is included among the top collaborators of Mark J. Mulligan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark J. Mulligan. Mark J. Mulligan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The two-dose MVA-BN mpox vaccine induces a nondurable and low avidity MPXV-specific antibody response 2025 ·Journal of Virology ·Aaron L. Oom, (unknown), (unknown), (unknown), Heekoung Youn, Michael Tuen, (unknown), Ashley Dumont, Hayley M. Belli, Jane R. Zucker, Jennifer B. Rosen, Ramin S. Herati, Marie I. Samanovic, Ralf Duerr, Angelica C Kottkamp, Mark J. Mulligan, (unknown)	7
2	A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of Nucleoside-Modified Messenger RNA Influenza Vaccines in Healthy Adults 2025 ·Vaccines ·Angela R Branche, Mark J. Mulligan, (unknown), Orlando Puente, (unknown), Graham Crowther, Agnieszka Zareba, (unknown), Ingrid L. Scully, Emily Gomme, Kenneth Koury, Nicholas Kitchin, (unknown), Annaliesa S. Anderson, Alejandra Gurtman, Kelly Lindert	3
3	Longitudinal study of immunity toSARS‐CoV2in ocrelizumab‐treatedMSpatients up to 2 years afterCOVID‐19 vaccination 2024 ·Annals of Clinical and Translational Neurology ·Ilya Kister, (unknown), Amanda L. Piquet, (unknown), Jinglan Pei, Barbara L. Banbury, Tamar Bacon, (unknown), Michael Tuen, (unknown), (unknown), (unknown), Marie I. Samanovic, Mark J. Mulligan, Y. Patskovsky, (unknown), (unknown), Ryan C. Winger, Michelle Krogsgaard, Gregg J. Silverman	2
4	Emergence and dissemination of SARS-CoV-2 XBB.1.5 in New York 2024 ·Virus Evolution ·Fabiana Gámbaro, Ralf Duerr, Dacia Dimartino, Christian Marier, Eduardo Iturrate, Mark J. Mulligan, Adriana Heguy, Simon Dellicour	2
5	The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studies 2023 ·Frontiers in Immunology ·Johannes B. Goll, Steven E. Bosinger, (unknown), Hasse Walum, (unknown), Gregory K. Tharp, Muktha S. Natrajan, Azra Blazevic, Richard D. Head, Casey E. Gelber, (unknown), Nirav Patel, Patrick Sanz, Nadine Rouphael, Evan J. Anderson, Mark J. Mulligan, Daniel F. Hoft	2
6	Immunogenicity and safety of varying dosages of a fifth-wave influenza A/H7N9 inactivated vaccine given with and without AS03 adjuvant in healthy adults 2023 ·Vaccine ·Lisa A. Jackson, Jack T. Stapleton, Emmanuel B. Walter, Wilbur H. Chen, Nadine Rouphael, Evan J. Anderson, Kathleen M. Neuzil, Patricia Winokur, Michael J. Smith, Kenneth E. Schmader, Geeta K. Swamy, (unknown), Mark J. Mulligan, Christina A. Rostad, Kaitlyn Cross, (unknown), (unknown), Paul C. Roberts	2
7	Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2–experienced individuals 2022 ·Science Translational Medicine ·Marie I. Samanovic, Amber Cornelius, (unknown), Joseph R. Allen, (unknown), (unknown), (unknown), Michael Tuen, Sergei B. Koralov, Mark J. Mulligan, Ramin S. Herati	45
8	Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes 2021 ·mBio ·Takuya Tada, Belinda M. Dcosta, Marie I. Samanovic, Ramin S. Herati, Amber Cornelius, Hao Zhou, (unknown), (unknown), Mark J. Mulligan, Nathaniel R. Landau	46
9	Proteomic Analysis of Human Immune Responses to Live-Attenuated Tularemia Vaccine 2020 ·Vaccines ·Yie‐Hwa Chang, Duc M. Duong, Johannes B. Goll, David C. Wood, (unknown), Luming Yin, Casey E. Gelber, Nicholas T. Seyfried, Evan J. Anderson, Muktha S. Natrajan, Nadine Rouphael, Robert A. Johnson, Patrick Sanz, Mark J. Mulligan, Daniel F. Hoft	6
10	Development and optimization of a Zika virus antibody-dependent cell-mediated cytotoxicity (ADCC) assay 2020 ·Journal of Immunological Methods ·Xuemin Chen, Larry J. Anderson, Christina A. Rostad, Lingmei Ding, Lilin Lai, Mark J. Mulligan, Nadine Rouphael, Muktha S. Natrajan, Courtney McCracken, Evan J. Anderson	8
11	Acceptability of an inactivated influenza vaccine delivered by microneedle patch: Results from a phase I clinical trial of safety, reactogenicity, and immunogenicity 2020 ·Vaccine ·Paula M. Frew, (unknown), Nadine Rouphael, (unknown), Yunmi Chung, Mark J. Mulligan, Mark R. Prausnitz	57
12	Caregiver and adolescent factors associated with delayed completion of the three-dose human papillomavirus vaccination series 2018 ·Vaccine ·Lea E. Widdice, Rebecca Hoagland, S. Todd Callahan, Jessica A. Kahn, Christopher J. Harrison, Barbara Pahud, Sharon E. Frey, Andrea A. Berry, Karen L. Kotloff, Kathryn M. Edwards, Mark J. Mulligan, (unknown), Aya Nakamura, David I. Bernstein	8
13	Antibody responses among adolescent females receiving two or three quadrivalent human papillomavirus vaccine doses at standard and prolonged intervals 2018 ·Vaccine ·Lea E. Widdice, Elizabeth R. Unger, Gitika Panicker, Rebecca Hoagland, S. Todd Callahan, Lisa A. Jackson, Andrea A. Berry, Karen L. Kotloff, Sharon E. Frey, Christopher J. Harrison, Barbara Pahud, Kathryn M. Edwards, Mark J. Mulligan, (unknown), David I. Bernstein	7
14	Systems Analysis of Immunity to Influenza Vaccination across Multiple Years and in Diverse Populations Reveals Shared Molecular Signatures 2015 ·Immunity ·Helder I. Nakaya, Thomas Hagan, Sai Duraisingham, Eva K. Lee, Marcin Kwissa, Nadine Rouphael, Daniela Frasca, Merril Gersten, Aneesh K. Mehta, Renaud Gaujoux, (unknown), Shakti Gupta, Rafi Ahmed, Mark J. Mulligan, Shai S. Shen-Orr, Bonnie B. Blomberg, Shankar Subramaniam, Bali Pulendran	211
15	The Yellow Fever Virus Vaccine Induces a Broad and Polyfunctional Human Memory CD8+ T Cell Response 2009 ·The Journal of Immunology ·Rama Akondy, (unknown), Joseph D. Miller, Srilatha Edupuganti, Dirk E. Teuwen, Hong Wu, (unknown), Seema Garg, John D. Altman, Carlos del Rı́o, Harry Keyserling, Alexander Ploß, Charles M. Rice, Walter A. Orenstein, Mark J. Mulligan, Rafi Ahmed	239
16	Molecular signature of human virus specific effector CD8+ T cells (83.20) 2009 ·The Journal of Immunology ·Rama Akondy, Joseph D. Miller, Gregory Doho, Hong Wu, Michael J. Zilliox, (unknown), Mark J. Mulligan, Srilatha Edupuganti, W. Nicholas Haining, Rafi Ahmed	1
17	Phase 2 Study of an HIV-1 Canarypox Vaccine (vCP1452) Alone and in Combination With rgp120 2006 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Nina D. Russell, Barney S. Graham, Michael C. Keefer, M. Juliana McElrath, Steve Self, Kent J. Weinhold, David C. Montefiori, Guido Ferrari, Helen Horton, Georgia D. Tomaras, Sanjay Gurunathan, Lynn Baglyos, Sharon E. Frey, Mark J. Mulligan, Clayton Harro, Susan Buchbinder, Lindsey R. Baden, William A. Blattner, Beryl A. Koblin, Lawrence Corey	69
18	Paucity of Antigen-Specific IgA Responses in Sera and External Secretions of HIV-Type 1-Infected Individuals 2004 ·AIDS Research and Human Retroviruses ·Jiří Městecký, Susan Jackson, Zina Moldoveanu, (unknown), Rose Kulhavy, S J Prince, Steffanie Sabbaj, Mark J. Mulligan, Paul A. Goepfert	93
19	T Cell Responses in HIV Type 1-Infected Adolescent Minorities Share Similar Epitope Specificities with Whites Despite Significant Differences in HLA Class I Alleles 2003 ·AIDS Research and Human Retroviruses ·Anju Bansal, Steffanie Sabbaj, Bradley H. Edwards, (unknown), (unknown), James Tang, James Szinger, Helen A. Weiss, Paul A. Goepfert, Bette Korber, Craig M. Wilson, Richard A. Kaslow, Mark J. Mulligan	16
20	UNDER THE INFLUENCE CHARACTERISTICS AND DRINKING PRACTICES OF PERSONS ARRESTED THE FIRST TIME FOR DRUNK DRIVING, WITH TREATMENT IMPLICATIONS 1975 ·Public Health Reports ·E W Fine, (unknown), Mark J. Mulligan	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact